Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22459568 | 0.94 | PPARG (0.39) | METAKR1B10AKR1B1NAAAPPARG | |
| SCHEMBL22459823 | 0.93 | THRB (0.44) | THRBCYP11B1CYP11B2MAPTPPARD | |
| SCHEMBL22459838 | 0.92 | MET (0.43) | METAKR1B10AKR1B1THRBALOX5 | |
| SCHEMBL22459335 | 0.90 | THRB (0.38) | METAKR1B10AKR1B1THRBPPARG | |
| SCHEMBL22459387 | 0.90 | POLB (0.40) | METAKR1B10AKR1B1NAAAPPARG | |
| SCHEMBL22459251 | 0.89 | THRB (0.38) | METAKR1B10AKR1B1THRBPPARG | |
| SCHEMBL22459362 | 0.89 | THRB (0.37) | THRBCYP11B1CYP11B2MAPTPPARD | |
| SCHEMBL22459349 | 0.88 | THRB (0.47) | METAKR1B10AKR1B1THRBNAAA | |
| SCHEMBL22459332 | 0.86 | PPARD (0.39) | CYP11B1CYP11B2MAPTPPARD | |
| SCHEMBL22459808 | 0.85 | TNKS2 (0.42) | METAKR1B10AKR1B1ALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725764-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, CCND1, CPNE4 | MET 3102/4885AKR1B10 3247/4885AKR1B1 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.